GlobeNewswire by notified

Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio

Share
  • Sandoz plans to acquire worldwide product rights for Mycamine®(micafungin sodium) from Astellas
  • Acquiring leading global echinocandin, one of three major antifungal classes, will significantly reinforce Sandoz hospital offering and leading anti-infectives portfolio
  • Addition of Mycamine®will support Sandoz global program to combat antimicrobial resistance (AMR) by targeted use of most appropriate therapies

Basel, January 24, 2023 – Sandoz, the global leader in off-patent (generic and biosimilar) medicines, has signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine® (micafungin sodium, Funguard® in Japan) from Astellas.

Closing is anticipated in the course of H1, 2023, subject to standard conditions and regulatory approvals.

Astellas reported Mycamine® sales of JPY 18.9 billion (USD 135 million) for the year ending March 31, 2022. The announcement comes after Sandoz successfully completed the acquisition of GSK’s global cephalosporins portfolio in October 2021.

Sandoz CEO Richard Saynor said: “Acquiring this leading and respected global brand will significantly reinforce the Sandoz global hospital offering, as well as complement our existing global leadership position in generic antibiotics.”

He added: “This will also be an important addition to our growing portfolio of anti-infective therapies aimed at combatting the spread of antimicrobial resistance, by providing the right drug to the right patient at the right time.”

Sandoz Anti-Infectives global medical lead Nicholas Adomakoh said: “Modern medicine is increasingly characterized by the need for complex interventions involving highly vulnerable patients. This welcome and timely portfolio addition will allow us to respond even better to the needs of patients and clinicians across the healthcare continuum.”

Mycamine®   is a leading global echinocandin, one of three major classes of antifungal agents, with a global patient base of well over two million. It   is a therapy of choice in hospitals and intensive care units worldwide, a proven prophylactic in hematology and oncology patients, and widely used in organ transplants.

Mycamine®   is indicated for treatment of invasive candidiasis and espophageal candidiasis, which are currently both on the rise with a higher occurrence of associated hospital outbreaks, as well as prevention of candida and aspergillus infections in patients undergoing hematopoietic stem cell transplantation.

Disclaimer 
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product’s label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

# # #

About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2021 sales of USD 9.6 billion.

Sandoz on social media:
LinkedIn: https://www.linkedin.com/company/sandoz
Twitter: https://twitter.com/sandoz_global
Facebook: https://www.facebook.com/sandozglobal/
Instagram: https://www.instagram.com/sandozglobal

CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor/

Sandoz Global Communications

CentralNorth America
Chris Lewis+49 174 244 9501Leslie Pott+1 609 627 5287
Novartis Media Relations
E-mail: media.relations@novartis.com

CentralNorth America
Richard Jarvis+41 79 584 2326Julie Masow+1 862 579 8456
Switzerland
Satoshi Sugimoto
+41 79 619 2035
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

CentralNorth America
Samir Shah+41 61 324 7944Sloan Simpson+1 862 345 4440
Nicole Zinsli-Somm+41 61 324 3809Parag Mahanti+1 973 876 4912
Isabella Zinck+41 61 324 7188
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Golar to acquire New Fortress Energy’s stake in FLNG Hilli6.2.2023 14:21:46 CET | Press release

Golar LNG Limited (“Golar” or “the Company”) has agreed to acquire the New Fortress Energy Inc. (“NFE”) ownership stake in FLNG Hilli in exchange for Golar’s remaining 4.1 million shares in NFE and $100 million in cash. Golar will also take over approximately $323 million in debt obligations linked to Hilli. Pursuant to the transaction, Golar will acquire the 50% interest in Trains 1 and 2 of FLNG Hilli, currently owned by a subsidiary of NFE. Following closing of the transaction, Golar’s effective interest in currently contracted FLNG Hilli earnings will be as follows: 94.55% of Common Units that receive tolling related fees relating to trains 1 and 2, and 5% of Dutch Title Transfer Facility (“TTF”) related fees,89.1% of Series A units that receive Brent oil related fees,89.1% of Series B units that receive 95% of TTF related fees. Following the transaction Golar will have no remaining shareholding in NFE. Commenting on the transaction, Golar CEO Karl Fredrik Staubo said “Today’s anno

Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)6.2.2023 14:00:00 CET | Press release

BOSTON and LONDON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the Company will present additional data from the open-label extension (OLE) of AP-0101, a Phase 2a study of SerpinPC, a novel inhibitor of activated protein C (APC) being developed for the treatment of hemophilia, during an oral presentation at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), on February 10, 2023. The Company recently announced positive results from the Phase 2a OLE at the 64th American Society of Hematology (ASH) Annual Meeting. “We are excited to share additional data from the OLE that further demonstrate the potential for SerpinPC to be a convenient subcutaneous treatment with a differentiated safety profile for people living with hemophilia,” said Saurabh Saha MD PhD, Chief Ex

Aktia’s Financial Statement Release 2023 will be published on Friday 17 February 2023 at 8.00 a.m.6.2.2023 14:00:00 CET | Press release

Aktia Bank Plc Press release 6 February 2023 at 03.00 p.m. Aktia’sFinancial Statement Release 2023 will be published on Friday17 February 2023 at 8.00 a.m. Aktia’s Financial Statement Release 2022 will be published on Friday 17 February 2023 at 8.00 a.m. (EET). The Financial Statement Release is available at Aktia’s website www.aktia.com after the publication. Webcast from the results event A live webcast will be sent from Aktia’s results event on Friday 17 February 2023 at 10.30 a.m. CEO Mikko Ayub and CFO Outi Henriksson will be presenting the results. The event will be held in English and can be seen live as a webcast or as a recording after the event at https://aktia.videosync.fi/2022-q4-results. The presentation material in English is available at Aktia’s website www.aktia.com before the results event. Aktia Bank Plc Further information: Lotta Borgström, Director, Investor Relations and Communications, tel. +358 10 247 6838, lotta.borgstrom@aktia.fi Distribution: Nasdaq Helsinki L

Aktias bokslutskommuniké för år 2022 publiceras fredagen 17.2.2023 kl. 8.006.2.2023 14:00:00 CET | Pressemelding

Aktia Bank Abp Pressmeddelande 6.2.2023 kl. 15.00 Aktias bokslutskommuniké för år 2022 publiceras fredagen 17.2.2023 kl. 8.00 Aktias bokslutskommuniké för år 2022 publiceras fredagen 17.2.2023 kl. 8.00. Bokslutskommunikén finns tillgänglig på Aktias webbplats på adressen www.aktia.com efter publiceringen. Webcast-sändning från resultattillställningen En direkt webcast-sändning arrangeras från Aktias resultattillställning fredagen 17.2.2023 kl. 10.30. Verkställande direktör Mikko Ayub och ekonomi- och finansdirektör Outi Henriksson presenterar resultatet. Tillställningen hålls på engelska och kan ses som en direkt webcast-sändning eller en inspelning efter tillställningen på adressen https://aktia.videosync.fi/2022-q4-results. Presentationsmaterialet på engelska finns tillgängligt på Aktias webbplats www.aktia.com före resultattillställningen. Aktia Bank Abp Mera information: Lotta Borgström, direktör för investerarrelationer och kommunikation, tfn 010 247 6838, lotta.borgstrom@aktia.fi

Bombardier CEO Éric Martel Evolves Leadership Team Structure as Part of Forward-Looking Growth Strategy, Building on Company Momentum6.2.2023 13:58:00 CET | Press release

Jean-Christophe Gallagher appointed Executive Vice President, Aircraft Sales and Bombardier Defense Paul Sislian appointed Executive Vice President of Bombardier Aftermarket Services & StrategyDavid Murray appointed Executive Vice President, Manufacturing, IT and Bombardier Operational Excellence SystemEric Filion joins Bombardier to the newly created role of Executive Vice President, Programs and Supply ChainMichel Ouellette will lead Engineering and Product Development until planned retirement later in 2023, following a 33-year, successful career MONTREAL, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Bombardier today announced a leadership team evolution that will focus on carrying forward the company’s positive momentum toward executing long-term growth and optimization strategies in the key areas of defense, services, continuous product improvement and next-generation manufacturing practices. “Bombardier has successfully embarked on its journey as a company focused on its world-class business